Researchers at The University of Texas Health Science Center at San Antonio (UT Health San Antonio) published a study analyzing more than 30 years of aging and dementia patterns of 678 nuns from the School Sisters of Notre Dame enrolled in the Nun Study, now housed at the school's Glenn Biggs Institute for Alzheimer's and Neurodegenerative Diseases.

A new pilot study known as STAMINA (Senolytics To Alleviate Mobility Issues and Neurological Impairments in Aging), that focused on the effects of senolytic medications, Dasatinib and Quercetin (DQ), which remove old (senescent) cells from the body, suggests that intermittent treatment may hold promise for improving cognitive function in older adults at risk of Alzheimer’s disease.

Rutgers Health researchers find that the diagnostic tools can be unreliable, particularly for Black patients.

Investigators from Mass General Brigham have conducted a multi-ancestry, whole genome sequencing association study of Alzheimer’s disease and found evidence for 16 new susceptibility genes, expanding the study of Alzheimer’s disease in underrepresented groups. Their results are published in Alzheimer’s & Dementia: The Journal of the Alzheimer’s Association.

Researchers from Cleveland Clinic’s Genome Center  outlined the pathway human herpes simplex virus-1 (HSV1) can use to contribute to Alzheimer’s disease in aging brains. In a report published in Alzheimer's & Dementia: The Journal of the Alzheimer's Association, investigators also share two FDA-approved, commercially available drugs that reverse this pathway in a laboratory setting.

The findings are the first concrete evidence to support the previously controversial link between human herpesviruses (HHVs) and Alzheimer’s disease.